Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.69
EPS est.
$-0.73
EPS surprise
+5.48%
1-day move
-3.43%
Denali Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the company did not generate any revenue, missing the consensus estimate of $2 million. The stock reacted negatively, declining by 3.43%, likely due to the lack of revenue and guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | $-0.71 | +5.48% |
| Revenue | — | $2M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. With a market cap of $3 billion, its work is particularly relevant as the aging population increases the prevalence of conditions like Alzheimer's and Parkinson's disease.
Last quarter
In the last quarter, Denali reported an EPS of $-0.73, slightly beating expectations but still reflecting ongoing losses. The stock price fell by nearly 4% the following day.
EPS beat streak
5Q
EPS beat rate
75%
Avg EPS surprise
+3.12%
Avg 1-day reaction
-2.11%
Analysts expect Denali to report a loss this quarter, with revenue figures that could vary widely. The market is cautious given the company's history of losses.
Bull case
If Denali can exceed revenue expectations and show signs of progress in its drug development pipeline, it could lead to a positive market reaction.
Bear case
Continued losses and lower-than-expected revenue could further dampen investor sentiment, especially if the company fails to provide clear guidance.
Key metrics to watch
EPS
$-0.71Earnings per share is a key indicator of profitability, and expectations are set at a loss of $0.71 this quarter.
Revenue
$2MRevenue figures will provide insight into the company's sales performance, with a consensus estimate of $2 million.
The print will turn on these.
Q1
Will Denali's revenue exceed the $2 million consensus estimate?
Revenue performance is critical for assessing the company's market traction and future funding needs.
Q2
What updates will management provide on their drug development pipeline?
Progress in clinical trials can significantly influence investor confidence and stock performance.
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Why consensus could be wrong
The consensus may underestimate Denali's potential for revenue growth due to its innovative pipeline, which could yield unexpected results.
Supporting evidence
The options market is pricing a 13.3% move, indicating expectations of significant volatility.
Denali has a history of beating EPS estimates, which could lead to a positive surprise this quarter.
Key risk
If revenue comes in significantly above $2 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining the company's trajectory amid ongoing losses and investor skepticism.
Bull confirmed if
Revenue exceeding $2 million and positive updates on drug trials would confirm a bullish outlook.
Bear confirmed if
If revenue falls below $1 million or there are delays in drug development, it would confirm a bearish outlook.
What the market is pricing for the move.
Implied Move
±13.3%
Historical Avg
±4.1%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±13.3% while DNLI has averaged ±4.1% over the last 8 prints — setup is pricing rich.
ATM IV
1.1%
30d HV
71.9%
Smart-money positioning from the most recent 13F filings.
Institutional
101.29%
of float
Insider
4.61%
of float
Holders
411
institutions
Top Holders· as of Jun 2026
T. Rowe Price Investment Management, Inc.
16,178,963 sh · $310.0M
10.12%
89.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Denali beats expectations, history suggests a potential average move of around -2.64%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty.
Miss
A miss could lead to a decline, with historical data indicating an average drop of -2.48% following such outcomes.
The lines on the call that would change the story.
Blackrock Inc.
14,026,413 sh · $268.7M
8.77%
7.6%
BAILLIE GIFFORD & CO
11,960,230 sh · $229.2M
7.48%
-0.9%
State Street Corporation
7,049,304 sh · $135.1M
4.41%
12.4%
Temasek Holdings (Private) Ltd
7,012,974 sh · $134.4M
4.39%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.